Carole E Aubert1, Sven Streit2, Bruno R Da Costa3, Tinh-Hai Collet4, Jacques Cornuz5, Jean-Michel Gaspoz6, Doug Bauer7, Drahomir Aujesky8, Nicolas Rodondi9. 1. Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland. Electronic address: caroleelodie.aubert@insel.ch. 2. Institute of Primary Health Care BIHAM, University of Bern, Switzerland. Electronic address: sven.streit@biham.unibe.ch. 3. Institute of Primary Health Care BIHAM, University of Bern, Switzerland. Electronic address: bruno.dacosta@biham.unibe.ch. 4. Service of Endocrinology, Diabetes and Metabolism, University Hospital of Lausanne, Switzerland; University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. Electronic address: tinh-hai.collet@chuv.ch. 5. Department of Ambulatory Care and Community Medicine, University of Lausanne, Switzerland. Electronic address: jacques.cornuz@chuv.ch. 6. Department of Community and General Medicine, Geneva University Hospital, Geneva, Switzerland. Electronic address: jean-michel.gaspoz@hcuge.ch. 7. Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, United States. Electronic address: dbauer@psg.ucsf.edu. 8. Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland. Electronic address: drahomir.aujesky@insel.ch. 9. Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Institute of Primary Health Care BIHAM, University of Bern, Switzerland. Electronic address: nicolas.rodondi@insel.ch.
Abstract
AIMS: Polypharmacy is associated with adverse events and multimorbidity, but data are limited on its association with specific comorbidities in primary care settings. We measured the prevalence of polypharmacy and inappropriate prescribing, and assessed the association of polypharmacy with specific comorbidities. METHODS: We did a cross-sectional analysis of 1002 patients aged 50-80years followed in Swiss university primary care settings. We defined polypharmacy as ≥5 long-term prescribed drugs and multimorbidity as ≥2 comorbidities. We used logistic mixed-effects regression to assess the association of polypharmacy with the number of comorbidities, multimorbidity, specific sets of comorbidities, potentially inappropriate prescribing (PIP) and potential prescribing omission (PPO). We used multilevel mixed-effects Poisson regression to assess the association of the number of drugs with the same parameters. RESULTS: Patients (mean age 63.5years, 67.5% ≥2 comorbidities, 37.0% ≥5 drugs) had a mean of 3.9 (range 0-17) drugs. Age, BMI, multimorbidity, hypertension, diabetes mellitus, chronic kidney disease, and cardiovascular diseases were independently associated with polypharmacy. The association was particularly strong for hypertension (OR 8.49, 95%CI 5.25-13.73), multimorbidity (OR 6.14, 95%CI 4.16-9.08), and oldest age (75-80years: OR 4.73, 95%CI 2.46-9.10 vs.50-54years). The prevalence of PPO was 32.2% and PIP was more frequent among participants with polypharmacy (9.3% vs. 3.2%, p<0.006). CONCLUSIONS: Polypharmacy is common in university primary care settings, is strongly associated with hypertension, diabetes mellitus, chronic kidney disease and cardiovascular diseases, and increases potentially inappropriate prescribing. Multimorbid patients should be included in further trials for developing adapted guidelines and avoiding inappropriate prescribing.
AIMS: Polypharmacy is associated with adverse events and multimorbidity, but data are limited on its association with specific comorbidities in primary care settings. We measured the prevalence of polypharmacy and inappropriate prescribing, and assessed the association of polypharmacy with specific comorbidities. METHODS: We did a cross-sectional analysis of 1002 patients aged 50-80years followed in Swiss university primary care settings. We defined polypharmacy as ≥5 long-term prescribed drugs and multimorbidity as ≥2 comorbidities. We used logistic mixed-effects regression to assess the association of polypharmacy with the number of comorbidities, multimorbidity, specific sets of comorbidities, potentially inappropriate prescribing (PIP) and potential prescribing omission (PPO). We used multilevel mixed-effects Poisson regression to assess the association of the number of drugs with the same parameters. RESULTS:Patients (mean age 63.5years, 67.5% ≥2 comorbidities, 37.0% ≥5 drugs) had a mean of 3.9 (range 0-17) drugs. Age, BMI, multimorbidity, hypertension, diabetes mellitus, chronic kidney disease, and cardiovascular diseases were independently associated with polypharmacy. The association was particularly strong for hypertension (OR 8.49, 95%CI 5.25-13.73), multimorbidity (OR 6.14, 95%CI 4.16-9.08), and oldest age (75-80years: OR 4.73, 95%CI 2.46-9.10 vs.50-54years). The prevalence of PPO was 32.2% and PIP was more frequent among participants with polypharmacy (9.3% vs. 3.2%, p<0.006). CONCLUSIONS: Polypharmacy is common in university primary care settings, is strongly associated with hypertension, diabetes mellitus, chronic kidney disease and cardiovascular diseases, and increases potentially inappropriate prescribing. Multimorbid patients should be included in further trials for developing adapted guidelines and avoiding inappropriate prescribing.
Authors: Luise Adam; Elisavet Moutzouri; Christine Baumgartner; Axel Lennart Loewe; Martin Feller; Khadija M'Rabet-Bensalah; Nathalie Schwab; Stefanie Hossmann; Claudio Schneider; Sabrina Jegerlehner; Carmen Floriani; Andreas Limacher; Katharina Tabea Jungo; Corlina Johanna Alida Huibers; Sven Streit; Matthias Schwenkglenks; Marco Spruit; Anette Van Dorland; Jacques Donzé; Patricia M Kearney; Peter Jüni; Drahomir Aujesky; Paul Jansen; Benoit Boland; Olivia Dalleur; Stephen Byrne; Wilma Knol; Anne Spinewine; Denis O'Mahony; Sven Trelle; Nicolas Rodondi Journal: BMJ Open Date: 2019-06-03 Impact factor: 2.692
Authors: Odilia I Woudstra; Joey M Kuijpers; Folkert J Meijboom; Marco C Post; Monique R M Jongbloed; Anthonie L Duijnhouwer; Arie P J van Dijk; Joost P van Melle; Thelma C Konings; Aeilko H Zwinderman; Barbara J M Mulder; Berto J Bouma Journal: Eur Heart J Cardiovasc Pharmacother Date: 2019-10-01
Authors: Yael Rachamin; Levy Jäger; Rahel Meier; Thomas Grischott; Oliver Senn; Jakob M Burgstaller; Stefan Markun Journal: Front Pharmacol Date: 2022-02-14 Impact factor: 5.810
Authors: Alexandra B Achterhof; Zsofia Rozsnyai; Emily Reeve; Katharina Tabea Jungo; Carmen Floriani; Rosalinde K E Poortvliet; Nicolas Rodondi; Jacobijn Gussekloo; Sven Streit Journal: PLoS One Date: 2020-10-26 Impact factor: 3.240